

# Product Data Sheet

## LEAF™ Purified anti-human G-CSF

**Catalog # / Size:** 502104 / 500 µg

**Clone:** BVD13-3A5

**Isotype:** Rat IgG1, κ

**Immunogen:** *E. coli*-expressed, recombinant human G-CSF


**Reactivity:** Human

**Preparation:** The LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.

**Formulation:** 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative. Endotoxin level is <0.1 EU/µg of the protein (<0.01 ng/µg of the protein) as determined by the LAL test.

**Concentration:** 1.0 mg/ml

**Storage:** The antibody solution should be stored undiluted at 4°C. This LEAF™ solution contains no preservative; handle under aseptic conditions.



## Applications:

**Applications:** ELISA Capture - *Quality tested*  
ELISPOT Capture, Neut, IHC - *Reported in the literature*

**Recommended Usage:** Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 1-4 µg/ml is recommended. It is recommended that the reagent be titrated for optimal performance for each application.

**Application Notes:** **ELISA or ELISPOT Capture<sup>1,2</sup>:** The Purified BVD13-3A5 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the biotinylated BVD11-37G10 antibody (Cat. No. 506702) as the detecting antibody. The LEAF™Purified antibody is suggested for ELISPOT capture.

**Application References:**

1. Abrams J. 1995. *Curr. Prot. Immunol.* John Wiley and Sons New York. Unit 6.20.
2. Abrams J, *et al.* 1992. *Immunol. Rev.* 127:5.
3. Andersson J, *et al.* 1994. *Immunology* 83:16.
4. Sander B, *et al.* 1991. *Immunol. Rev.* 119:65.
5. Andersson U, *et al.* 1999. *Detection and quantification of gene expression.* New York:Springer-Verlag.

**Description:** Granulocyte - colony stimulating factor (G-CSF) is a potent stimulator of bone marrow cells especially those of neutrophilic granulocyte lineage. In addition, G-CSF can enhance the survival and activate the immunological functions of mature neutrophils. G-CSF is produced primarily by monocytes and macrophages upon activation by endotoxin, TNF-alpha or IFN-gamma. The BVD13-3A5 antibody reacts with human granulocyte-colony stimulating factor (G-CSF). The BVD13-3A5 antibody can neutralize the bioactivity of natural or recombinant G-CSF.

**Antigen References:**

1. Fitzgerald K, *et al.* Eds. 2001. *The Cytokine FactsBook.* Academic Press San Diego.
2. Demetri G, *et al.* 1991. *Blood* 78:2791.
3. Moore M. 1991. *Annu. Rev. Immunol.* 9:159.
4. Negrin R, *et al.* 1992. *Adv. Pharmacol.* 23:263.

**Related Products:**

<b>Product</b>	<b>Clone</b>	<b>Application</b>
Recombinant Human G-CSF		BA, ELISA
LEAF™ Purified Rat IgG1, κ Isotype Ctrl	RTK2071	FC, ICFC, WB, IP, ICC, IF, IHC, FA



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.



\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biollegend.com/ordering#license](http://www.biollegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.